Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2021

01-01-2021 | Vascular Biology (H. Pownall, Section Editor)

AIBP, Angiogenesis, Hematopoiesis, and Atherogenesis

Authors: Xueting Qiu, Jingmin Luo, Longhou Fang

Published in: Current Atherosclerosis Reports | Issue 1/2021

Login to get access

Abstract

Purpose of Review

The goal of this manuscript is to summarize the current understanding of the secreted APOA1 binding protein (AIBP), encoded by NAXE, in angiogenesis, hematopoiesis, and inflammation. The studies on AIBP illustrate a critical connection between lipid metabolism and the aforementioned endothelial and immune cell biology.

Recent Findings

AIBP dictates both developmental processes such as angiogenesis and hematopoiesis, and pathological events such as inflammation, tumorigenesis, and atherosclerosis.

Summary

Although cholesterol efflux dictates AIBP-mediated lipid raft disruption in many of the cell types, recent studies document cholesterol efflux-independent mechanism involving Cdc42-mediated cytoskeleton remodeling in macrophages. AIBP disrupts lipid rafts and impairs raft-associated VEGFR2 but facilitates non-raft–associated NOTCH1 signaling. Furthermore, AIBP can induce cholesterol biosynthesis gene SREBP2 activation, which in turn transactivates NOTCH1 and supports specification of hematopoietic stem and progenitor cells (HSPCs). In addition, AIBP also binds TLR4 and represses TLR4-mediated inflammation. In this review, we summarize the latest research on AIBP, focusing on its role in cholesterol metabolism and the attendant effects on lipid raft–regulated VEGFR2 and non-raft–associated NOTCH1 activation in angiogenesis, SREBP2-upregulated NOTCH1 signaling in hematopoiesis, and TLR4 signaling in inflammation and atherogenesis. We will discuss its potential therapeutic applications in angiogenesis and inflammation due to selective targeting of activated cells.
Literature
1.
Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation. J Immunol. 2010;184(1):173–83.PubMed
2.
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134(1):97–111.PubMedPubMedCentral
3.
Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 2012;11(2):195–206.PubMedPubMedCentral
4.
Westerterp M, Tsuchiya K, Tattersall IW, Fotakis P, Bochem AE, Molusky MM, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in endothelial cells accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2016;36(7):1328–37.PubMedPubMedCentral
5.
Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689–93.PubMedPubMedCentral
6.
7.
Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331–40.PubMed
8.
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–45.PubMed
9.
Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity. 2013;38(1):92–105.PubMed
10.
Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000;97(22):12097–102.PubMedPubMedCentral
11.
Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383(6602):728–31.PubMed
12.
Ritter M, Buechler C, Boettcher A, Barlage S, Schmitz-Madry A, Orso E, et al. Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. Genomics. 2002;79(5):693–702.PubMed
13.••
••Fang L, Choi SH, Baek JS, Liu C, Almazan F, Ulrich F, et al. Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature. 2013;498(7452):118–22 This is the first study to show that AIBP-mediated cholesterol efflux disrupts lipid rafts, impairs raft-associated VEGFR2 signaling, and thereby limits angiogenesis.
14.
Mao R, Meng S, Gu Q, Araujo-Gutierrez R, Kumar S, Yan Q, et al. AIBP limits angiogenesis through gamma-secretase-mediated upregulation of notch signaling. Circ Res. 2017;120(11):1727–39.PubMedPubMedCentral
15.
Fang L, Miller YI. Regulation of lipid rafts, angiogenesis and inflammation by AIBP. Curr Opin Lipidol. 2019;30(3):218–23.PubMedPubMedCentral
16.
17.
Westerterp M. AIBP decreases atherogenesis by augmenting cholesterol efflux. Atherosclerosis. 2018;273:117–8.PubMed
18.••
••Gu Q, Yang X, Lv J, Zhang J, Xia B, Kim JD, et al. AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate. Science. 2019;363(6431):1085–8 Findings from this study reveal a novel paradigm of SREBP2-transactivated NOTCH signaling in the regulation of hematopoiesis in development and in hyperlipidemia.
19.
• Low H, Mukhamedova N, Capettini LDSA, Xia Y, Carmichael I, Cody SH, et al. Cholesterol efflux-independent modification of lipid rafts by AIBP (apolipoprotein A-I binding protein). Arterioscler Thromb Vasc Biol. 2020;40(10):2346–2359. https://​doi.​org/​10.​1161/​ATVBAHA.​120.​315037. This paper unveils that AIBP induces CDC42 activation, which disrupts lipid rafts via cytoskeletal change but not cholesterol efflux.
20.
Liao H, Langmann T, Schmitz G, Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22(1):127–32.PubMed
21.
Stefulj J, Panzenboeck U, Becker T, Hirschmugl B, Schweinzer C, Lang I, et al. Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ Res. 2009;104(5):600–8.PubMed
22.
O'Connell BJ, Denis M, Genest J. Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation. 2004;110(18):2881–8.PubMed
23.
Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289(5484):1524–9.PubMed
24.
Yamauchi Y, Iwamoto N, Rogers MA, Abe-Dohmae S, Fujimoto T, Chang CC, et al. Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J Biol Chem. 2015;290(39):23464–77.PubMedPubMedCentral
25.
Chen J, Zhao L, Sun D, Narsinh K, Li C, Zhang Z, et al. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice. Inflamm Res. 2012;61(12):1299–307.PubMed
26.
Fielding PE, Nagao K, Hakamata H, Chimini G, Fielding CJ. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry. 2000;39(46):14113–20.PubMed
27.
Savion N, Kotev-Emeth S. Cholesterol efflux from and high-density-lipoproteins binding to cultured bovine vascular endothelial cells are higher than with vascular smooth muscle cells. Eur J Biochem. 1989;183(2):363–70.PubMed
28.
Jin X, Dimitriadis EK, Liu Y, Combs CA, Chang J, Varsano N, et al. Macrophages shed excess cholesterol in unique extracellular structures containing cholesterol microdomains. Arterioscler Thromb Vasc Biol. 2018;38(7):1504–18.PubMedPubMedCentral
29.
Sezgin E, Levental I, Mayor S, Eggeling C. The mystery of membrane organization: composition, regulation and roles of lipid rafts. Nat Rev Mol Cell Biol. 2017;18(6):361–74.PubMedPubMedCentral
30.
Zhu Y, Liao HL, Wang N, Yuan Y, Ma KS, Verna L, et al. Lipoprotein promotes caveolin-1 and Ras translocation to caveolae: role of cholesterol in endothelial signaling. Arterioscler Thromb Vasc Biol. 2000;20(11):2465–70.PubMed
31.
Fu Y, Hoang A, Escher G, Parton RG, Krozowski Z, Sviridov D. Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J Biol Chem. 2004;279(14):14140–6.PubMed
32.
Le Lay S, Rodriguez M, Jessup W, Rentero C, Li Q, Cartland S, et al. Caveolin-1-mediated apolipoprotein A-I membrane binding sites are not required for cholesterol efflux. PLoS One. 2011;6(8):e23353.PubMedPubMedCentral
33.
Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293(5539):2449–52.PubMed
34.
Fernandez-Hernando C, Yu J, Suarez Y, Rahner C, Davalos A, Lasuncion MA, et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab. 2009;10(1):48–54.PubMedPubMedCentral
35.
36.
Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13(7):868–73.PubMedPubMedCentral
37.
Stahl A, Sapieha P, Connor KM, Sangiovanni JP, Chen J, Aderman CM, et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res. 2010;107(4):495–500.PubMedPubMedCentral
38.
Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F, et al. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arterioscler Thromb Vasc Biol. 2012;32(9):2280–8.PubMed
39.
Zhou RH, Yao M, Lee TS, Zhu Y, Martins-Green M, Shyy JY. Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis. Circ Res. 2004;95(5):471–8.PubMed
40.
Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab. 2013;17(4):549–61.PubMedPubMedCentral
41.
Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, et al. Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol. 2014;34(2):279–84.PubMed
42.
43.
Zhu X, Westcott MM, Bi X, Liu M, Gowdy KM, Seo J, et al. Myeloid cell-specific ABCA1 deletion protects mice from bacterial infection. Circ Res. 2012;111(11):1398–409.PubMedPubMedCentral
44.
Sumi M, Sata M, Miura S, Rye KA, Toya N, Kanaoka Y, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27(4):813–8.PubMed
45.
van Oostrom O, Nieuwdorp M, Westerweel PE, Hoefer IE, Basser R, Stroes ES, et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2007;27(8):1864–5.PubMed
46.
Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, Kardassis D. HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. Metabolism. 2018;87:36–47.PubMed
47.
Cannizzo CM, Adonopulos AA, Solly EL, Ridiandries A, Vanags LZ, Mulangala J, et al. VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia. FASEB J. 2018;32(6):2911–22.PubMed
48.
Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem. 2013;288(29):21237–52.PubMedPubMedCentral
49.
Prosser HC, Tan JT, Dunn LL, Patel S, Vanags LZ, Bao S, et al. Multifunctional regulation of angiogenesis by high-density lipoproteins. Cardiovasc Res. 2014;101(1):145–54.PubMed
50.
Cartier A, Leigh T, Liu CH, Hla T. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci U S A. 2020;117(6):3157–66.PubMedPubMedCentral
51.
Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011;108(23):9613–8.PubMedPubMedCentral
52.
Liu M, Allegood J, Zhu X, Seo J, Gebre AK, Boudyguina E, et al. Uncleaved ApoM signal peptide is required for formation of large ApoM/sphingosine 1-phosphate (S1P)-enriched HDL particles. J Biol Chem. 2015;290(12):7861–70.PubMedPubMedCentral
53.
Yanagida K, Hla T. Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient. Annu Rev Physiol. 2017;79:67–91.PubMed
54.
Tatematsu S, Francis SA, Natarajan P, Rader DJ, Saghatelian A, Brown JD, et al. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb Vasc Biol. 2013;33(8):1788–94.PubMedPubMedCentral
55.
Jin F, Hagemann N, Sun L, Wu J, Doeppner TR, Dai Y, et al. High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation. Angiogenesis. 2018;21(2):381–94.PubMed
56.
Zhu L, Parker M, Enemchukwu N, Shen M, Zhang G, Yan Q, et al. Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun Biol. 2020;3(1):386.PubMedPubMedCentral
57.
Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.PubMedPubMedCentral
58.
Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, et al. Pro-angiogenic macrophage phenotype to promote myocardial repair. J Am Coll Cardiol. 2019;73(23):2990–3002.PubMed
59.
Zhang T, Wang Q, Wang Y, Wang J, Su Y, Wang F, et al. AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux. J Transl Med. 2019;17(1):161.PubMedPubMedCentral
60.
Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931–9.PubMedPubMedCentral
61.
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71(18):6073–83.PubMed
62.
Siekmann AF, Covassin L, Lawson ND. Modulation of VEGF signalling output by the Notch pathway. Bioessays. 2008;30(4):303–13.PubMed
63.
Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196–208.PubMed
64.
Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, et al. Association of active gamma-secretase complex with lipid rafts. J Lipid Res. 2005;46(5):904–12.PubMed
65.
Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160(1):113–23.PubMedPubMedCentral
66.
Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer’s disease. Lancet Neurol. 2005;4(12):841–52.PubMed
67.
Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003;24(5):637–43.PubMed
68.
Chang TY, Yamauchi Y, Hasan MT, Chang C. Cellular cholesterol homeostasis and Alzheimer’s disease. J Lipid Res. 2017;58(12):2239–54.PubMedPubMedCentral
69.
Karten B, Vance DE, Campenot RB, Vance JE. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem. 2002;83(5):1154–63.PubMed
70.
Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, et al. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005;280(27):25892–900.PubMedPubMedCentral
71.
Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol. 2004;167(5):953–60.PubMedPubMedCentral
72.
Chen Z, Wen L, Martin M, Hsu CY, Fang L, Lin FM, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation. 2015;131(9):805–14.PubMed
73.
Yeh M, Cole AL, Choi J, Liu Y, Tulchinsky D, Qiao JH, et al. Role for sterol regulatory element-binding protein in activation of endothelial cells by phospholipid oxidation products. Circ Res. 2004;95(8):780–8.PubMed
74.
Kim JY, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, et al. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell. 2018;175(1):133–45 e15.PubMedPubMedCentral
75.
Mayneris-Perxachs J, Puig J, Burcelin R, Dumas ME, Barton RH, Hoyles L, et al. The APOA1bp-SREBF-NOTCH axis is associated with reduced atherosclerosis risk in morbidly obese patients. Clin Nutr. 2020;39:3408–18.PubMed
76.
Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003;100(21):12027–32.PubMedPubMedCentral
77.
78.
Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, et al. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res. 2013;112(10):1345–54.PubMedPubMedCentral
79.
Nguyen DH, Taub D. Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5. Blood. 2002;99(12):4298–306.PubMed
80.
81.
Schneider DA, Choi SH, Agatisa-Boyle C, Zhu L, Kim J, Pattison J, et al. AIBP protects against metabolic abnormalities and atherosclerosis. J Lipid Res. 2018;59(5):854–63.PubMedPubMedCentral
82.
Zhang M, Li L, Xie W, Wu JF, Yao F, Tan YL, et al. Apolipoprotein A-1 binding protein promotes macrophage cholesterol efflux by facilitating apolipoprotein A-1 binding to ABCA1 and preventing ABCA1 degradation. Atherosclerosis. 2016;248:149–59.PubMed
83.
Woller SA, Choi SH, An EJ, Low H, Schneider DA, Ramachandran R, et al. Inhibition of neuroinflammation by AIBP: spinal effects upon facilitated pain states. Cell Rep. 2018;23(9):2667–77.PubMedPubMedCentral
84.
Harari OA, Alcaide P, Ahl D, Luscinskas FW, Liao JK. Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res. 2006;98(9):1134–40.PubMedPubMedCentral
85.
Miller YI, Shyy JY. Context-dependent role of oxidized lipids and lipoproteins in inflammation. Trends Endocrinol Metab. 2017;28(2):143–52.PubMed
86.
Ding Y, Subramanian S, Montes VN, Goodspeed L, Wang S, Han C, et al. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(7):1596–604.PubMedPubMedCentral
87.
Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009;458(7242):1191–5.PubMed
88.
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154–62.PubMed
89.
Zhang M, Zhao GJ, Yin K, Xia XD, Gong D, Zhao ZW, et al. Apolipoprotein A-1 binding protein inhibits inflammatory signaling pathways by binding to apolipoprotein A-1 in THP-1 macrophages. Circ J. 2018;82(5):1396–404.PubMed
90.
Zhang M, Zhao GJ, Yao F, Xia XD, Gong D, Zhao ZW, et al. AIBP reduces atherosclerosis by promoting reverse cholesterol transport and ameliorating inflammation in apoE(-/-) mice. Atherosclerosis. 2018;273:122–30.PubMed
91.
Shumilin IA, Cymborowski M, Chertihin O, Jha KN, Herr JC, Lesley SA, et al. Identification of unknown protein function using metabolite cocktail screening. Structure. 2012;20(10):1715–25.PubMedPubMedCentral
92.
93.
Choi SH, Kim KY, Perkins GA, Phan S, Edwards G, Xia Y, et al. AIBP protects retinal ganglion cells against neuroinflammation and mitochondrial dysfunction in glaucomatous neurodegeneration. Redox Biol. 2020;37:101703.PubMedPubMedCentral
94.
de Aguiar Vallim TQ, Lee E, Merriott DJ, Goulbourne CN, Cheng J, Cheng A, et al. ABCG1 regulates pulmonary surfactant metabolism in mice and men. J Lipid Res. 2017;58(5):941–54.PubMedPubMedCentral
95.
Becker-Kettern J, Paczia N, Conrotte JF, Zhu C, Fiehn O, Jung PP, et al. NAD(P)HX repair deficiency causes central metabolic perturbations in yeast and human cells. FEBS J. 2018;285(18):3376–401.PubMed
96.
Kremer LS, Danhauser K, Herebian D, Petkovic Ramadza D, Piekutowska-Abramczuk D, Seibt A, et al. NAXE mutations disrupt the cellular NAD(P)HX repair system and cause a lethal neurometabolic disorder of early childhood. Am J Hum Genet. 2016;99(4):894–902.PubMedPubMedCentral
97.
98.
Metadata
Title
AIBP, Angiogenesis, Hematopoiesis, and Atherogenesis
Authors
Xueting Qiu
Jingmin Luo
Longhou Fang
Publication date
01-01-2021
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 1/2021
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-020-00899-9

Other articles of this Issue 1/2021

Current Atherosclerosis Reports 1/2021 Go to the issue

Vascular Biology (H. Pownall, Section Editor)

High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis

Statin Drugs (R. Ceska, Section Editor)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

Statin Drugs (R. Ceska, Section Editor)

Should We Target Global Risk or Risk Factors?

Reviews and New Research Implications (S. Virani, Section Editor)

Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits